Related Experiment Videos
Hodgkin lymphoma in pregnancy
Veronika Bachanova1, Joseph M Connors
1University of Minnesota, Minneapolis, 55455, USA. bach0173@umn.edu
Current Hematologic Malignancy Reports
|June 11, 2013
Summary
Managing Hodgkin lymphoma (HL) during pregnancy requires a multidisciplinary team to optimize maternal cure and fetal health. Treatment is individualized based on disease stage, gestational age, and patient preference.
Area of Science:
- Oncology
- Maternal-Fetal Medicine
- Hematology
Background:
- Hodgkin lymphoma (HL) incidence peaks during reproductive years.
- Approximately 3% of HL patients present with concurrent pregnancy.
- Managing pregnant HL patients necessitates a multidisciplinary approach.
Purpose of the Study:
- To outline optimal management strategies for pregnant patients with Hodgkin lymphoma.
- To balance maternal cancer treatment with fetal well-being.
- To provide guidance on individualized treatment decisions.
Main Methods:
- Clinical examination for staging.
- Judicious use of non-radiation imaging (e.g., ultrasound).
- Individualized treatment planning based on symptoms, stage, and gestational age.
Main Results:
- Management requires collaboration between medical oncology, high-risk obstetrics, and neonatology.
- Treatment options range from deferral to single-agent vinblastine.
- Multi-agent chemotherapy is reserved for aggressive cases in later trimesters.
Conclusions:
- Individualized, multidisciplinary care is crucial for pregnant HL patients.
- Treatment decisions must weigh maternal cure potential against fetal delivery of a healthy child.
- Non-radiation diagnostic methods are preferred for staging.
Related Concept Videos
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:27Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:15Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:27Ovarian Cycle
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...